Integrating manufacturing and sales in regenerative medicine
First written in FY2023. 5 of 7 entries say "Advanced", first in FY2024-Q1. Latest entry: 2026-09-14.
0 other companies' latest entry also says "Advanced".
- FY2025RestatedAnnual report
「In the Medical Support business, we are developing an end-to-end business combining the company’s outsourced sales services for blood-derived processing in regenerative medicine with the manufacturing technology and expertise of our wholly owned subsidiary, Cellpro Japan Co., Ltd.」
The company continues its policy of end-to-end manufacturing and sales of blood-derived processing services based on its wholly owned relationship with Cellpro Japan. - FY2024AdvancedAnnual report
「We are developing an end-to-end business combining the company’s outsourced sales services for blood-derived processing in regenerative medicine with the manufacturing technology and expertise of our wholly owned subsidiary, Cellpro Japan Co., Ltd.」
After full subsidiarization, the company progressed to end-to-end manufacturing and sales of blood-derived processing services. - FY2024-Q2AdvancedAnnual report
「To strengthen integrated manufacturing and sales of outsourced blood-derived processing services in regenerative medicine, we have strengthened close cooperation among staff and begun planning and developing high-value-added cosmetics and other products using Cellpro Japan’s technology and expertise.」
After Cellpro Japan became a wholly owned subsidiary, the company strengthened staff coordination toward integrated manufacturing and sales and began product development using Cellpro Japan’s technology and expertise. - FY2024-Q1AdvancedAnnual report
「Effective 1 January 2024, we conducted a share exchange under which the company became the wholly owning parent company and Cellpro Japan Co., Ltd. became a wholly owned subsidiary.」
The full subsidiarization of Cellpro Japan, which owns the manufacturing technology, moved the plan to integrate manufacturing and sales into the legal group-integration stage. The business benefits of this integration were described as future developments. - FY2023First statedAnnual report
「For a company like ours, which only provides outsourced sales services for blood-derived processing, incorporating Cellpro Japan’s manufacturing technology and expertise and integrating manufacturing technology with sales services on an end-to-end basis has long been a major objective.」
The company planned to integrate manufacturing and sales functions for blood-derived processing services through its alliance with SBC Medical Group and the full subsidiarization of Cellpro Japan.